SOLUTION OVERVIEW

DIA-AID integrates advanced multi-omics analysis (genetics, proteomics, and immune-response data) with AI-driven interpretation to rapidly detect infectious pathogens and identify antibiotic resistance. This streamlined, data-rich approach offers high diagnostic accuracy in hours—not days—saving critical time in patient care and reducing unnecessary antibiotic use.

EXAMPLES OF USE CASES

1. Neonatal Sepsis
   In premature infants, traditional tests often fail due to limited blood volume and an underdeveloped immune system. DIA-AID’s minimal-sample approach and high sensitivity ensure rapid detection of life-threatening infections, guiding precise treatment early on.

2. Pneumonia in the Elderly
   Older adults can quickly deteriorate if treatment is delayed or incorrect. DIA-AID distinguishes bacterial from viral or fungal causes, helping clinicians select the right therapy and prevent complications like sepsis.

3. Immunocompromised Patients
   Individuals with weakened immunity—such as those undergoing chemotherapy—need rapid and specific diagnostic insights. DIA-AID spots co-infections and emerging resistance markers, making sure treatment is always one step ahead.

SIGNIFICANCE AND IMPACT

• Antibiotic resistance results in over 1.5 billion euros in annual healthcare costs in the EU alone.
• A 2050 projection warns that drug-resistant infections may surpass cancer as a leading cause of death worldwide.
• Global leaders at the United Nations have pledged to reduce antibiotic-resistant deaths by 10% by 2030, highlighting the urgent need for more effective diagnostic solutions.

By rapidly identifying pathogens and resistance profiles, DIA-AID aligns with these international goals, aiming to cut both medical costs and mortality rates.

TEAM & EXPERTISE

DIA-AID is driven by a multidisciplinary group of entrepreneurs, researchers, and healthcare experts. Our backgrounds span molecular biotechnology, AI algorithm development, clinical practice, and business strategy. Together, we are committed to delivering transformative diagnostic solutions that improve patient outcomes and optimize healthcare resources.

SUPPORTING EVIDENCE

Antimicrobial resistant pathogens already kill more people annually than any single infectious disease. In 2019, nearly 5 million deaths were linked to AMR, including 1.4 million in South Asia and 1 million in Sub-Saharan Africa in 2019.

Of the 5 million deaths linked to AMR — more than 1 million are in children aged under 5 years.

A study published in The Lancet (2024) estimated that AMR was responsible for one million deaths annually between 1990 and 2021, and the Institute for Health Metrics and Evaluation at the University of Washington estimates that AMR will be responsible for approximately 39 million deaths between 2025 and 2050. 

A new UN report predicts that by 2050, if nothing changes, there will be a 780% increase in mortality caused by AMR infections, and hence equal cancer as the leading cause of death.
Finally, the World Health Organization estimates that AMR could result in approximately $3.4 trillion in gross domestic product losses by 2030.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

https://www.healthdata.org/research-analysis/health-risks-issues/antimicrobial-resistance-amr

https://www.who.int/teams/immunization-vaccines-and-biologicals/product-and-delivery-research/anti-microbial-resistance

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext
https://www.worldbank.org/en/search?q=antimicrobial+resistance

https://healthpolicy-watch.news/antimicrobial-resistance-deaths-cancer/